News
Cortex’s CEO Roger Stoll to Speak at the Bank of Montreal’s Focus on Healthcare Conference
Event to be Held at New York City’s Millennium Broadway Hotel December 4-5, 2007
Irvine, CA (November 28, 2007) — Cortex Pharmaceuticals, Inc. (AMEX: COR, http://www.cortexpharm.com) Chairman, President and CEO, Roger G. Stoll, PhD, will speak at the Bank of Montreal’s Focus on Healthcare Conference taking place December 4 - 5, 2007, at the Millennium Broadway Hotel in New York City. Dr. Stoll will give the company presentation on Wednesday, December 5 at 9:00 AM (EST). The conference will feature a small, select group of companies spanning all sectors of healthcare.
Dr. Stoll will provide an update on recent clinical, regulatory, and research activities related to their Ampakine® technology platform and discuss relevant financial and business development activities at Cortex.
The conference presentation will be webcast and available for a period of thirty days after the conference by logging on to: http://www.bmocm.com/conferences/2007healthcare/.
Cortex Pharmaceuticals, Inc.
Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. Cortex is pioneering a class of proprietary pharmaceuticals called Ampakine compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer’s disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain’s neurotransmitter system. These imbalances may be improved by using the Ampakine technology. Cortex has an alliance with N.V. Organon for the treatment of schizophrenia and depression. In December 2006 Cortex terminated the research collaboration with Servier enabling Cortex to pursue the use of Ampakine compounds in the treatment of neurodegenerative diseases on a global basis. Servier retained the right to select up to three compounds developed during the collaboration for further development for the treatment of neurodegenerative diseases. Cortex may receive additional milestones and royalties if either Organon or Servier is successful in developing and commercializing Ampakine compounds. For additional information regarding Cortex, please visit Cortex Pharmaceuticals’ website at www.cortexpharm.com.
Forward-Looking Statement
Note - This press release contains forward-looking statements concerning the Company’s research and development activities. The success of such activities depends on a number of factors, including the risks that the Company’s proposed compounds may at any time be found to be unsafe or ineffective for the indications under clinical test and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. The forward-looking statements are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Cortex, all as more fully described in the risk factors and other matters set forth in Cortex’s Annual Report on Form 10-K for the year ended December 31, 2006, and Cortex’s other filings with the Securities and Exchange Commission, As discussed in the Company’s Securities and Exchange Commission filings, the Company’s proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. Ampakine compounds are investigational drugs and have not been approved for the treatment of any disease. Cortex disclaims any intent or obligation to update any forward-looking statements.
Contacts:
Roger G. Stoll, Ph.D.
Chairman, President and CEO
Cortex Pharmaceuticals, Inc.
(949) 727-3157
Erika Moran/Dian Griesel, Ph.D.
The Investor Relations Group
(212) 825-3210 |